The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2Breceptor by Betti, Marco et al.
20 December 2021
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine
A2Breceptor / Betti, Marco; Catarzi, Daniela; Varano, Flavia; Falsini, Matteo; Varani, Katia; Vincenzi, Fabrizio; Ben,
Diego Dal; Lambertucci, Catia; Colotta, Vittoria. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN
0223-5234. - STAMPA. - 150(2018), pp. 127-139. [10.1016/j.ejmech.2018.02.081]
Original Citation:
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-





(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1118554 since: 2021-03-29T12:04:13Z
Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:
FLORE






The aminopyridine-3,5-dicarbonitrile core for the design of 
new non-nucleoside-like agonists of the human adenosine A2B 
receptor 
 
Marco Betti,a Daniela Catarzi,a* Flavia Varano,a Matteo Falsini,a Katia Varani,b Fabrizio Vincenzi,b 
Diego Dal Ben,c Catia Lambertucci,c Vittoria Colottaa 
 
aDipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di 
Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, 50019 Sesto 
Fiorentino, Italy; bDipartimento di Scienze Mediche, Sezione di Farmacologia, Università degli Studi 
di Ferrara, Via Fossato di Mortara 17-19, 44121 Ferrara, Italy; cScuola di Scienze del Farmaco e 
dei Prodotti della Salute, Università degli Studi di Camerino, Via S. Agostino 1, 62032 Camerino 
(MC), Italy.  
 
AUTHOR INFORMATION  
Corresponding author *Tel: +39 055 4573722. e-mail: daniela.catarzi@unifi.it   
ORCID: Daniela Catarzi 0000-0002-8821-928X 
 
Highlights 
 amino-3,5-dicyanopyridines were developed as novel adenosine hA2B receptor agonists 
 some compounds showed nanomolar potency and partial or full agonism at the hA2B AR  





A new series of amino-3,5-dicyanopyridines (3-28) as analogues of the adenosine hA2B receptor 
agonist BAY60-6583 (compound 1) was synthesized. All the compounds that interact with the hA2B 
adenosine receptor display EC50 values in the range 9-350 nM behaving as partial agonists, with the 
only exception being the 2-{[4-(4-acetamidophenyl)-6-amino-3,5-dicyanopyridin-2-
yl]thio}acetamide (8) which shows a full agonist profile. Moreover, the 2-[(1H-imidazol-2-
yl)methylthio)]-6-amino-4-(4-cyclopropylmethoxy-phenyl)pyridine-3,5-dicarbonitrile (15) turns out 
to be 3-fold more active than 1 although less selective. This result can be considered a real 
breakthrough due to the currently limited number of non-adenosine hA2B AR agonists reported in 
literature. To simulate the binding mode of nucleoside and non-nucleoside agonists at the hA2B AR, 
molecular docking studies were performed at homology models of this AR subtype developed by 
using two crystal structures of agonist-bound A2A AR as templates. These investigations allowed us 
to represent a hypothetical binding mode of hA2B receptor agonists belonging to the amino-3,5-
dicyanopyridine series and to rationalize the observed SAR. 
 
Key words: G protein-coupled receptors, adenosine A2B receptor agonists, aminopyridine-3,5-
dicarbonitriles, ligand-adenosine receptor modelling studies. 
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Adenosine (Ado) is an endogenous purine nucleoside that normally increases under pathological or 
stressful situations producing its effects through activation of G protein–coupled adenosine receptors 
(ARs). These latter, classified as A1, A2A, A2B, and A3, are typically coupled to adenylate cyclase but 
other second messenger systems have also been described [1,2]. Over the years, many ligands, 
agonists and antagonists, have been identified for the A1, A2A, and A3 ARs that, in turn, have been 
extensively characterized [3]. In contrast, the A2B AR subtype is the least known. In fact, while a 
large number of selective A2B AR antagonists belonging to different chemical classes has been 
developed [4-10], only a few A2B AR agonists are known so far [11]. As antagonists are characterized 
by a large structural variability, the agonist profile has been long associated to an Ado-like structure. 
Starting from the 5′-(N-ethylcarboxamido)adenosine (NECA), the first Ado-derived nucleosidic 
human (h) A2B AR agonist, a slightly more potent hA2B agonist than NECA was identified [12]. 
Fortunately, progress has been made. In fact, the non-Ado-like 2-{[6-Amino-3,5-dicyano-4-(4-
(cyclopropylmethoxy)phenyl)pyridin-2-yl]thio}acetamide (BAY60-6583, compound 1), a 2-
aminopyridine-3,5-dicarbonitrile derivative (Chart 1) discovered by Bayer Healthcare [13,14], is the 
only available potent and selective hA2B AR agonist reported so far. Its identification has invalidated 
the conviction that the sugar moiety is essential for agonism at ARs, such that non-nucleoside ligands 
must therefore behave as antagonists. Thus, compound 1 has been used extensively as a research tool 
to clarify the pharmacological roles of A2B AR [15-28] sometimes leading to contradictory results 
[29]. Thus, it could be a very important goal to obtain other potent and selective hA2B AR agonists 
especially considering the difficulties that have emerged in understanding of the pharmacological 
properties of A2B AR agonists and the necessity to explain some controversies concerning the A2BAR 
[29]. In particular, the amino-3,5-dicyanopyridine series, to which compound 1 belongs, has been 
demonstrated to include partial agonists with a variable maximum agonist effect at the hA2B AR 
subtype [30]. More recently, two different papers reported the partial agonist profile of 1 [27,31] and 




Chart 1. Lead structures for the development of currently reported amino-3,5-dicyanopyridine-based 
AR ligands. 
 
In this scenario, our research group focused attention on the aminopyridine-3,5-dicarbonitrile series 
to broaden the scarcely known structure-activity relationships (SARs) of this chemical class. In fact, 
most of the non-Ado-like AR ligands belonging to this series are included in patent documents 
[12,13,21] while few data are reported in the open literature [30,33,34]. These are, however, sufficient 
to underline the versatility of the amino-3,5-dicyanopyridine scaffold for producing AR ligands with 
not only a wide range of affinities but, interestingly, with different degrees of efficacy, ranging from 
full to partial agonist or neutral antagonist at the different ARs. In particular, certain 2-amino-4-aryl-
6-(1H-imidazol-2-yl-methylsulfanyl)-pyridine-3,5-dicarbonitriles belonging to the LUF series [30] 
(2, Chart 1) displayed nanomolar affinity for all the ARs, including the A2B AR subtype on which 
they showed, in general, also considerable efficacy. Moreover, this class of compounds seems to be 
more versatile for pharmacological studies showing less species differences than the Ado-like AR 
agonists [3]. It is worth noting that in addition to compound 1, that reached preclinical-phase 
investigation for treating angina pectoris, also other amino-3,5-dicyanopyridine derivatives 
discovered by Bayer Healthcare have attracted attention for their potential in heart diseases [32, 34]. 
Thus, taking compound 1 as lead, modifications on the amino-3,5-dicyanopyridine core were 




Chart 2. Modification performed at R1 and R2 positions of the 2-amino-4-aryl-6-sulfanyl-3,5-


















RESULTS AND DISCUSSION 
Chemistry 
The synthetic pathways which yielded compounds 1, 3-28, 52 and the relative intermediates are 
illustrated in Schemes 1-3. The amino-3,5-dicyanopyridine derivatives 1, 3-28 [13,21] (Scheme 1) 
were obtained starting from aldehydes 29-35, all commercially available with the exception of the 4-
(cyclobuthylmethoxy)benzaldehyde 29 [35] which was obtained by reacting 4-hydroxybenzaldehyde 
with (bromomethyl)cyclobutane in refluxing acetone and in the presence of potassium carbonate. By 
one-pot cyclization of the suitable aldehyde 29-33, 35 with malononitrile and thiophenol, the 
sulfanylphenyl intermediates 37-41, 43 were obtained. Different cyclization alkaline adjuvants able 
to work in a phase-transfer system were used, the best being DBU [36]. Moderate to good yields were 
obtained. Differently, the para-acetamido-benzaldehyde 34 was reacted with malononitrile in a 
straightforward Knoevenagel condensation in the presence of a few drops of piperidine as catalyst to 
give the intermediate 36 [37]. The latter was reacted with malononitrile in a cyclization reaction 














































R1 compound R1 compound 
O
 
3, 29, 37, 44 O
 
7, 33, 41, 48 
O
 
4, 30, 38, 45 NHCOCH3 8, 34, 36, 42, 49 
O  5, 25-27, 31, 39, 46 O  1, 9-24, 35, 43, 50 
O  6, 28, 32, 40, 47   
  
Reagents and conditions. a) To yield compound 29: BrCH2C4H7, acetone, anhydrous K2CO3, reflux 
(67%); compounds 30-35 are commercially available; b) malononitrile, thiophenol, DBU, 10% 
aqueous EtOH, 55 °C (18-37%); c) malononitrile, piperidine, EtOH, 80 °C (63%); d) malononitrile, 
thiophenol, Et3N, EtOH, reflux (44%); e) Na2S, anhydrous DMF, 80 °C; 1M HCl, rt (72-86%); f) 
R2CH2X (X = Cl, Br), NaHCO3, anhydrous DMF, rt (19-80%). 
 
To obtain the free thiols (compounds 44-50 [13,37,38]), the corresponding 6-phenylsulfanyl 
derivatives 37-43 [37] were treated with sodium sulfide in DMF at 80 °C followed by 1M HCl. The 
final compounds 3-28 were obtained by reaction of the 6-thiol-derivatives 44-50 with the suitable 
halides in the presence of sodium hydrogencarbonate. These latter were all commercially available 
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with the exception of the 2-chloro-N-hydroxyacetamide 51 [39] which was synthesized from ethyl 2-
chloroacetate with 50% aqueous solution of hydroxylamine as reported in Scheme 2. 
 
Scheme 2  
 
Reagents and conditions. a) 50% aqueous NH2OH, rt (53%). 
 
Moreover, the hA2B AR agonist 1 [13,21] was cyclized in absolute ethanolic potassium hydroxide to 
yield the bicyclic compound 52 (Scheme 3). The forced alkaline conditions produced the 
condensation of the 3-cyano substituent with the active methylene group on the sulfanylacetamide 




Reagents and conditions. a) KOH, absolute EtOH, reflux (85%). 
 
 
Pharmacological Assays  
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The newly synthesized derivatives 3-28, 52 and the reference compound 1 were studied as hA2B AR 
agonists by evaluating their stimulatory effect on cAMP production in Chinese Hamster Ovary (CHO) 
cells, stably expressing the hA2B AR. Some selected compounds (3, 12, 17, 18, 21-23, 28) were 
evaluated also in cAMP production in hA2BCHO cells as hA2B AR antagonists at 1µM concentration 
in the presence of NECA 100 nM. Moreover, their affinities at hA1, hA2A, and hA3 ARs, stably 
transfected in CHO cells, were measured. All pharmacological data are presented in Table 1.  
 

















   cAMP assays Binding experimentsa 
   EC50 (nM)b Efficacy,
c % Ki (nM) or I% 




 CONH2 - 5% 1% 5% 1% 
4 O  CONH2 - 1% 603± 52 307 ±27 9% 
5 O  CONH2 38±3 66% 345±27 1% 20% 
6g O
 
CONH2 - 11% 323 ±25 18% 444 ±39 
7 O
 





CONH2 164±12 92% 17% 572±51 742±67 
9 O  CONHCH3 94±8 63% 14% 1% 3% 
10 O  CONHCH2OH 182±14 57% 10% 1% 8% 
11 O  CONHOH - 20% 536 ± 49 1% 31% 
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a Ki values are means ± SEM of four separate assays each performed in triplicate. Percentage of inhibition (I%) 
is determined at 1µM concentration of the tested compounds.  
b EC50 values are means ± SEM of four separate assays each performed in triplicate.  
c Efficacy of the tested compound at 1µM concentration, in comparison with NECA (1µM = 100%). 
d Displacement of specific [3H]DPCPX competition binding to hA1CHO cells. 
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- 1% 67±7 424±37 19% 
25 O  CONHCH3 211 ±17 48% 104 ±8 8% 834 ±74 




11.7±1.2 62% 8.2±0.7 221±19 85±6 










- 7% 44 ±4 8% 13% 
52 - - - 1% 19% 3% 13% 
1g,h O  CONH2 31±3 100% 31% 2% 8% 
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e Displacement of specific [3H]ZM241385 competition binding to hA2ACHO cells. 
f Displacement of specific [125I]AB-MECA competition binding to hA3CHO cells.  
g Reference [13]. 
h Reference [21]. 
 
Structure-activity relationships 
The pharmacological data for the newly synthesized amino-3,5-dicyanopyridine derivatives 3-28 are 
reported in Table 1 together with those of the reference compound 1 [13,21]. Most of the compounds 
have generally low to null hA2A and hA3 AR affinity while the binding at the hA1 AR subtype depends 
strictly on both R1 and R2 substituents. All the derivatives that interact with the hA2B AR (5, 8-10, 
13-16, 19, 20, 25-27) display EC50 values from 9.5 to 347 nM behaving as partial agonists, with the 
only exception being compound 8 [13] which shows a full agonist profile. Moreover, derivative 15 
that merges the typical R1 and R2 substituents of compound 1 and series 2, respectively (Chart 1), 
turns out to be the most potent hA2B receptor agonist among this series (EC50 = 9.5 nM) and is also 
endowed with good selectivity versus the other ARs (25-fold vs hA1 AR, 80-fold vs hA2A AR, and 
50-fold vs hA3 AR). Some compounds (3, 12, 17, 18, 21-23 and 28), selected among those that had 
no activity at the hA2B AR, were evaluated also as hA2B AR antagonists revealing the inability to 
inhibit NECA-stimulated cAMP levels. 
First, to explore how slight modifications of the para-cyclopropylmethyloxy group of the lead 
compound 1 could influence hA2B AR activity and selectivity, 2-sulfanylacetamido-derivatives 3-7 
bearing different cycloalkyl- or cycloalkenyl-methyloxy substituents at R1 position were synthesized. 
These compounds totally lose hA2B AR activity except for the para-ethoxy-substituted derivative 5 
which is as potent as 1. In contrast, the 4-(para-acetamidophenyl)-substituted derivative 8 is endowed 
with good activity at the hA2B AR despite a low selectivity versus hA2A and hA3 AR subtypes. The 
latter is the only amino-3,5-dicyanopyridine in the whole series having a full agonist profile at the 
hA2B AR. The para-acetamido substituent, in addition to possessing an oxygen atom as H-bond 
acceptor, also contains the NH donor group that could have some influence in determining the 
pharmacological profile of this derivative as observed for series 2 [51,52]. When position R2 was 
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modified by introducing carboxamido bioisosteres (compounds 9-14), best results were obtained in 
terms of hA2B AR activity and selectivity. In fact, the N-methylacetamido compound 9 and its 
analogous N-hydroxymethylacetamido 10 are active at the hA2B AR, compound 9 also being the most 
selective within the herein reported series. In contrast, the hydroxamic acid derivative 11 loses its 
potency, probably due to the acidity of its R2 residue which is scarcely tolerated by the hA2B AR. Aryl 
homologation of the lead 1 yielded compound 13 which is highly potent at the hA2B AR subtype thus 
confirming how both H-bond acceptor and donor functions at this position are essential for hA2B AR-
ligand interaction. Also, the ameliorative π-stacking contribution of the phenyl moiety at R2 cannot 
be ignored leading to a great increase of binding affinity at the A1 subtype. 
Starting from the imidazole idea (see series 2, Chart 1), compound 15 was prepared and it emerged 
as a very potent hA2B AR agonist being 3-fold more active than the reference agonist 1. Moreover, it 
shows good selectivity versus the other AR subtypes and a partial agonist profile. Thus, the imidazolyl 
moiety at R2 was replaced with diverse H-bond donor/acceptor-groups containing heterocycles to 
yield the subset of compounds 16-24. All derivatives that interact with hA2B AR behave as partial 
agonist as 15. First, compound 16 bearing an imidazol-5-yl moiety at R2 was produced, resulting less 
active than its isomer 15 at the hA2B AR, but also at the other ARs. Compound 19, bearing a 3-
pyrazolyl group, shows a good hA2B AR affinity that is comparable with that of the 1,2,4-triazol-5-yl 
derivative 20. These data, together with the inactivity of compound 23, confirm again the importance 
of the presence of H-bond acceptor/donor functions at R2. Also tetrazolyl-substitution (compound 21) 
results as detrimental for hA2B AR activity, probably due to the excessive acidity of the NH tetrazole 
moiety, as observed for the idroxamic acid derivative 11.  
Furthermore, selecting the best R1 and R2 substituents in terms of hA2B AR activity, compounds 25-
27 were synthesized bearing the 4-(para-ethyloxy) group as a common feature. The potency value of 
compound 26 confirms the favourable effect exerted by the imidazolyl moiety on hA2B AR interaction 
making this compound as potent as derivative 15. In contrast, 26 also shows high hA1 AR affinity, 
thus suggesting the cyclopropylmethyloxy substituent as suitable for obtaining potent hA2B AR 
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agonists endowed with better selectivity versus the other ARs. The same positive effect on hA1 AR 
binding is produced by the pyrazolyl group which increases the affinity for this subtype in both 
derivatives 27 and 28 with respect to the corresponding 2-sulfanylacetamido compounds 5 and 6 [13]. 
Finally, the bicyclic compound 52, which was originated by intramolecular cyclization of the parent 
compound 1, does not bind any of the ARs thus suggesting that this kind of molecular complication, 
which makes the structure more rigid, is detrimental for the profitable interaction with hARs and in 
particular with the A2B AR subtype. 
Molecular Modelling Studies  
To simulate the binding mode of nucleoside and non-nucleoside agonists at hA2B AR, molecular 
docking studies were performed on homology models of hA2B AR developed using two crystal 
structures of agonist-bound hA2A AR [43, 44] as templates (pdb code: 2YDO; 3.0-Å resolution [45] 
and pdb code: 3QAK; 2.7-Å resolution [46], in complex with Ado and 6-(2,2-diphenylethylamino)-
9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl]-N-{2-[3-(1-(pyridin-2-
yl)piperidin-4-yl)ureido]ethyl}-9H-purine-2-carboxamide, also named UK-432097, respectively). 
The obtained hA2B AR homology models were checked using the Protein Geometry Monitor 
application within MOE (Molecular Operating Environment 2014.09) [47], with inspection of the 
structural quality of the protein models (backbone bond lengths, angles and dihedrals, Ramachandran 
φ-ψ dihedral plots, and quality of side chain rotamer and non-bonded contact). The two hA2B AR 
structures were then used as target for the docking analysis of the synthesized derivatives, whose 
structures were optimized using RHF/AM1 semi-empirical calculations (using software package 
MOPAC implemented in MOE) [48]. The docking studies were performed by using the MOE docking 
tool and Gold and Autodock software [49-51]. The MOE software analysis was made by selecting 
the induced fit docking and optimization protocol (Schematically, a preliminary docking analysis 
provides a set of ligand conformations that are energy minimized, including in this step the side chains 
of the receptor residues in proximity). For each compound, the top-score docking pose at each hA2B 
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AR model, according to at least two out of three scoring functions, was selected for final ligand-target 
interaction analysis. 
We decided to employ two homology models of the hA2B AR to consider slightly different 
arrangements of the binding cavities and hence to better explore the conformational variability of the 
target pocket. Homology models of the hA2B AR built on the same two templates were used for 
previously reported docking studies with non-nucleoside hAR agonists [51]; the 3QAK A2A AR 
crystal structure was used as target for docking studies of non-nucleoside agonists of this receptor 
[52], as well as an X-ray structure of the same protein very similar to the 2YDO structure employed 
as template in this study (pdb code: 2YDV [45]).  
As previously described [51], the binding cavities of the two hA2B AR models are similar, considering 
both receptor residues orientation and pocket volumes. The differences are due to diverse 
arrangements of some residues, like a glutamate residue (Glu174, corresponding to Glu169 in hA2A 
AR) located within extracellular loop (EL) 2 segment and making an H-bond interaction with the N6-
amino group of Ado in the 2YDO crystal structure. This residue is differently oriented in the 3QAK 
X-ray. For the non-nucleoside agonist binding, the role of this amino acid does not appear to be 
critical, according to mutagenesis studies performed at A2A AR [52]. The different arrangements of 
this residue can slightly change the space available at the entrance of the binding cavity, but have a 
marginal effect on the size and chemical-physical properties of the binding site. This could explain 
why we observed analogous results by comparing the obtained docking conformations at the two 
cavities. The Supporting Information section contains a figure showing the two hA2B AR model 
pockets with the docked compound 15.  
For the sake of clarity, in this section, the position numbering of the substituents on the pyridine 
nucleus is defined as in compound 15. Thus, starting from the N1 position, it is assumed that the 
amino and sulfanyl groups occupy positions 2 and 6, respectively. The simulated binding mode 
associated to the best score, in the great majority of cases presents the compounds oriented similarly 




Figure 1. Docking conformation of compound 15 at the hA2B AR receptor model (the 2YDO-based 
one). Global (A) and top (B) view are displayed. Key residues for ligand-target interaction are 
indicated. 
 
In detail, the pyridine scaffold is located in the hA2B AR cavity in correspondence to the purine moiety 
of Ado or UK-432097 observed from hA2A AR templates. The heterocyclic core is stabilized within 
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the cavity by interaction with Phe173 (EL2) and Ile2767.39.  Both the 3-cyano and the 2-amino groups 
make a polar interaction with the amide function of Asn2546.55. Considering the 2YDO-based hA2B 
AR model, the 2-amino substituent gives a H-bond interaction with Glu174, while in the case of the 
3QAK-based model such interaction is not present due to a different arrangement of the glutamate. 
In some cases, the N1 atom makes a polar interaction with Lys269 (EL3). The 5-cyano group on the 
pyridine core gets in proximity of His2807.43 and transmembrane (TM) 2 residues. As previously 
suggested in analogue studies at the hA2A AR [52], the interaction with these amino acids could be 
mediated by a bridge water molecule or by a protonated state of His2807.43 in which its polar hydrogen 
could be oriented toward the 3-cyano group. The 6-sulfanyl substituent (Fig. 1B) is located at the 
entrance of the cavity getting close to residues of TM1, TM2, TM7 domains (Tyr101.35, Ser682.65, and 
Asn2737.36, respectively) and EL2 segment (Leu172 and Phe173). Considering the heterocycle-
containing 6-substituents, a series of potential interactions with these residues may be observed (see 
compounds 15, 16, 19 and 20). Figure 1B shows the imidazol-2-yl moiety appended on the 6-sulfanyl 
group of 15. A partial π-stacking interaction is observed with Tyr101.35. The partial reduction of the 
imidazole ring of 15 (i.e. compound 17) leads to a fall of hA2B AR activity, possibly due to the loss 
of this π-stacking interaction. Polar interactions are given by the imidazol-2-yl moiety with the polar 
hydrogen atom of the backbone amino group of Phe173 and with the carbonyl group of the Asn2737.36 
side chain. Replacement of the 2-imidazolyl group with a 4-imidazolyl substituent (compound 16) 
affords a decrease of activity, probably due to the loss of the interaction with Phe173 polar hydrogen. 
Other modifications of this ring through the introduction of other nitrogen-containing heterocycles 
(i.e. 19-21, 23) leads to a decrease or a loss of hA2B AR activity. The presence in R
2
 of a phenyl ring 
substituted with an amide or an ester function (compounds 13 and 14, respectively), still maintains 
activity at the hA2B AR, confirming the importance of the presence of groups able to provide H-bond 
interaction at this level. Compounds bringing an amide function within the R2 substituent are 
generally endowed with activity at the hA2B AR. This may be interpreted by considering that this 
functional group mimics the combination of H-bond donor and acceptor functions of the 2-imidazolyl 
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ring and is able to provide a double polar interaction with Phe173 and Asn2737.36 as observed for 
compound 15. On the other hand, the activity of the compounds is influenced by the structural and 
chemical properties of the 4-substituent. In this docking arrangement, this group gets in proximity of 
Leu863.33, Thr893.36, Trp2476.48, His2516.52 and, partially, Ser2797.42, and His2807.43. The volume of 
the substituent (R1) at the para-position of the 4-phenyl ring appears a critical feature for activity of 
the compounds, with a cyclopropylmethyloxy function providing the best results at the A2B AR. 
Docking results show this group located deep in the binding cavity within a narrow hydrophobic sub-
pocket that is suitable to accommodate the para-cycloalkyl group. This observation helps to interpret 
the decrease or loss of activity of compounds featuring a para-substituent with higher hindrance than 
the cyclopropylmethyloxy one (i.e. compound 3). Also, the presence of a smaller para-ethyloxy group 
(compounds 5, 25-27) maintains the activity at the hA2B AR although depending on the R2 
substituents as observed in the case of the corresponding para-cyclopropylmethyloxyphenyl-
substituted derivatives 1, 9, 15, 19. 
An alternative binding mode orients the compounds in a different way with respect to the above 
described docking conformations, and similarly to the one previously described in the literature at 




The present study has led to the identification of some potent hA2B AR ligands with a partial agonist 
profile, several of which are also endowed with good selectivity towards the other AR subtypes. The 
2-[(1H-imidazol-2-yl)methylthio)]-6-amino-4-(4-cyclopropylmethoxy-phenyl)pyridine-3,5-
dicarbonitrile 15 emerged as the most interesting compound being also 3-fold more active than the 
lead 1. This result can be considered a real breakthrough due to the currently limited number of non-
Ado-like hA2B AR agonists reported in the literature. The results of the docking studies at two hA2B 
AR homology models allowed us to interpret the interaction features of the amino-3,5-
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dicyanopyridine derivatives at this receptor, also providing useful indications for the design of new 




Chemistry. Analytical silica gel plates (Merck F254), preparative silica gel plates (Merck F254, 2 
mm) and silica gel 60 (Merck, 70-230 mesh) were used for analytical and preparative TLC, and for 
column chromatography, respectively. All melting points were determined on a Gallenkamp melting 
point apparatus and are uncorrected. Elemental analyses were performed with a Flash E1112 
Thermofinnigan elemental analyzer for C, H, N and the results were within ±0.4% of the theoretical 
values. All final compounds revealed purity not less than 95%. The IR spectra were recorded with a 
Perkin-Elmer Spectrum RX I spectrometer in Nujol mulls and are expressed in cm-1. NMR spectra 
were recorded on a Bruker Avance 400 spectrometer (400 MHz for 1H NMR and 100 MHz for 13C 
NMR). The chemical shifts are reported in δ (ppm) and are relative to the central peak of the residual 
nondeuterated solvent, which was CDCl3 or DMSOd6. The following abbreviations are used: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, Ar = aromatic protons, eq = 
equatorial and ax = axial. 
 
General Procedure for the Synthesis of 6-Substituted 2-Amino-4-aryl-3,5-dicyanopyridine 
Derivatives 1, 3-21, 23, 25-28 [13,21] and 2-Substituted 6-Amino-4-aryl-3,5-dicyanopyridines 22, 
24.  
Sodium hydrogen carbonate (2.0 mmol) and the suitable halomethyl-derivative (1.0 mmol) were 
consequentially added to a solution of the sulfanyl compound 44-50 [13,37,38] (1.0 mmol) in 
anhydrous DMF (1 mL). The reaction mixture was stirred at rt until the disappearance of the starting 
material (TLC monitoring). At reaction completion, water was added (25 mL) to precipitate a solid 
which was collected by filtration and triturated with Et2O (5 mL). The crude product was purified by 
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column chromatography (compounds 4, 7, 16, 26, 27), preparative TLC (17, 28) or recrystallized (1, 
3, 5, 6, 8-15, 18-25).  
2-{[6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl]thio}acetamide 1 [13,21]. 
Yield 40%; mp 219-220 °C (MeOH); 1H NMR (DMSO-d6) 8.00 (br s, 2H, NH2), 7.45-7.55 (m, 3H, 
Ar + NH), 7.25 (s, 1H, NH), 7.10 (d, 2H, Ar, J= 8.7 Hz), 3.91 (d, 2H, OCH2, J= 7.0 Hz), 3.88 (s, 2H, 
SCH2), 1.23-1.29 (m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 0.34-0.38 (m, 2H, CHax). Anal. Calcd for 
C19H17N5O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-(cyclobutylmethoxy)phenyl)pyridin-2-yl]thio}acetamide 3. 
Yield 21%; mp 244-246 °C (EtOAc/cyclohexane); 1H NMR (DMSO-d6) 7.99 (br s, 2H, NH2), 7.50-
7.47 (m, 3H, Ar + NH), 7.49 (d, 2H, Ar, J= 8.6 Hz), 7.26 (s, 1H, NH), 7.10 (d, 2H, Ar, J= 8.6 Hz), 
4.04 (d, 2H, OCH2, J= 6.7 Hz), 3.88 (s, 2H, SCH2), 2.78- 2.71 (m, 1H, CH), 1.99-1.82 (m, 6H, 3CH2); 
IR 3664, 3361, 3252, 2214, 1635. Anal. Calcd for C20H19N5O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-isobutoxyphenyl)pyridin-2-yl]thio}acetamide 4. 
Yield 21%; column chromatography, eluting system CH2Cl2/MeOH, 9.7:0.3; mp 233-235 °C (EtOH); 
1H NMR (DMSO-d6) 7.99 (br s, 2H, NH2), 7.49-7.47 (m, 3H, Ar + NH), 7.25 (s, 1H, NH), 7.11 (d, 
2H, Ar, J= 8.8 Hz), 3.88 (s, 2H, SCH2), 3.84 (d, 2H, OCH2, J= 6.4 Hz), 2.08-2.02 (m, 1H, CH), 1.01 
(d, 6H, 2CH3, J= 6.8 Hz); IR 3537, 3375, 3196, 2208, 1639. Anal. Calcd for C19H19N5O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-ethoxyphenyl)pyridin-2-yl]thio}acetamide 5. 
Yield 35%; mp 235-237 °C (EtOH); 1H NMR (DMSO-d6) 7.98 (br s, 2H, NH2), 7.50 (s, 1H, NH), 
7.48 (d, 2H, Ar, J= 8.8 Hz), 7.23 (s, 1H, NH), 7.10 (d, 2H, Ar, J= 8.8 Hz), 4.12 (q, 2H, OCH2, J= 7.2 
Hz), 3.88 (s, 2H, SCH2), 1.36 (t, 3H, CH3, J= 7.2 Hz,); IR 3396, 3180, 2210, 1637. Anal. Calcd for 
C17H15N5O2S. 
2-{[4-(4-(Allyloxy)phenyl)-6-amino-3,5-dicyanopyridin-2-yl]thio)}acetamide 6 [13]. 
Yield 67%; mp 204-206 °C (EtOH); 1H NMR (DMSO-d6) 8.00 (s, 2H, NH2), 7.50 (m, 3H, Ar + NH), 
7.26 (s, 1H, NH), 7.14 (d, 2H, Ar, J = 8.7 Hz), 5.98-6.18 (m, 1H, CH), 5.45 (dd, 1H, CH, J = 17.3, 
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1.4 Hz), 5.30 (dd, 1H, CH, J = 10.5, 1.4 Hz), 4.67 (d, 2H, OCH2, J = 5.1 Hz), 3.89 (s, 2H, SCH2); IR 
3325, 3215, 3184, 2212. Anal. Calcd for C18H15N5O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-[(2-methylallyl)oxy]phenyl)pyridin-2-yl]thio}acetamide 7. 
Yield 27%; column chromatography, eluting system EtOAc/cyclohexane/MeOH, 5:5:1); mp 224-226 
°C (EtOH); 1H NMR (DMSO-d6) 7.99 (s, 2H, NH2), 7.51 (s, 1H, NH), 7.50 (d, 2H, Ar, J= 8.6 Hz), 
7.25 (s, 1H, NH), 7.13 (d, 2H, Ar, J= 8.6 Hz), 5.10 (s, 1H, CH), 4.99 (s, 1H, CH), 4.57 (s, 2H, OCH2), 
3.88 (s, 2H, SCH2), 1.08 (s, 3H, CH3); IR 3481, 3334, 3234, 2212, 1681. Anal. Calcd for 
C19H17N5O2S. 
2-{]4-(4-Acetamidophenyl)-6-amino-3,5-dicyanopyridin-2-yl]thio}acetamide 8 [13]. 
Yield 19%; 279-281 °C (MeOH); 1H NMR (DMSO-d6) 10.2 (br s, 1H, NH), 7.99 (br s, 2H, NH2), 
7.74 (d, 2H, Ar, J= 7.6 Hz), 7.49-7.47 (m, 3H, Ar + NH), 7.24 (s, 1H, NH), 3.89 (s, 2H, SCH2), 2.09 
(s, 3H, CH3); 
13C NMR (DMSO-d6): 169.38, 169.27, 166.67, 160.10, 158.52, 141.70, 129.72, 128.44, 
119.12, 115.82, 93.65, 86.29, 33.78, 24.57; IR 3419, 3367, 2208, 1647. Anal. Calcd for C17H14N6O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl]thio}-N-methylacetamide 
9. 
Yield 71%; mp 274-276 °C (Acetone); 1H NMR (DMSO-d6) 8.20-7.90 (bm, 3H, NH2 + NH), 7.47 
(d, 2H, Ar, J = 8.7 Hz), 7.09 (d, 2H, Ar, J = 8.7 Hz), 3.85-3.95 (m, 4H, SCH2 + OCH2), 2.62 (d, 3H, 
CH3, J = 4.6 Hz), 1.23-1.30 (m, 1H, CH), 0.57-0.61 (m, 2H, CHeq), 0.34-0.38 (m, 2H, CHax); 
13C 
NMR (DMSO-d6): 167.79, 166.54, 160.76, 160.16, 158.59, 130.64, 126.04, 115.90, 115.00, 93.70, 
86.24, 72.75, 33.73, 26.56, 10.53, 3.61. IR 3390, 3323, 3223, 2208. Anal. Calcd for C20H19N5O2S. 
2-{[6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl]thio}-N-(hydroxymethyl)- 
acetamide 10. 
Yield 79%; mp 202-204°C (MeOH); 1H NMR (DMSO-d6) 8.69 (t, 1H, NH, J= 6.3 Hz); 7.8-8.2 (br s, 
2H, NH2), 7.46-7.50 (m, 2H, Ar), 7.08-7.12 (m, 2H, Ar), 5.72 (t, 1H, OH, J = 6.42 Hz), 4.53 (t, 2H, 
NCH2O, J= 6.00), 3.90-3.92 (m, 4H, 2CH2), 1.22-1.29 (m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 0.34-





Yield 60%; mp 176-178 °C (EtOH); 1H NMR (DMSO-d6) 10.58 (br s, 1H, OH), 9.06 (br s, 1H, NH), 
8.01 (br s, 2H, NH2), 7.48 (d, 2H, Ar, J = 8.6 Hz,), 7.10 (d, 2H, Ar, J = 8.6 Hz), 3.91 (d, 2H, SCH2, J 
= 6.9 Hz), 3.81 (s, 2H, OCH2), 1.27-1.24 (m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 0.37 – 0.42 (m, 2H, 
CHax); IR 3649, 3331, 3223, 2208. Anal. Calcd for C19H17N5O3S. 
Methyl 2-{[6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl]thio}acetate 12. 
Yield 41%; mp 205-207 °C (EtOH); 1H NMR (DMSO-d6) 7.9 (br s, 2H, NH2), 7.48 (d, 2H, ar J= 8.8), 
7.1 (d, 2H, ar, J= 8.8), 4.20 (s, 2H, SCH2), 3.91 (d, 2H, OCH2, J= 7.0), 3.69 (s, 3H, OCH3), 1.24-1.28 
(m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 0.35-0.38 (m, 2H, CHax); IR 3446, 3342, 3224, 2210, 1739. 
Anal. Calcd for C20H18N4O3S 
3-{[(6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl)thio]methyl}benzamide 
13. 
Yield 47%; mp 243-245 °C (EtOAc/2-methoxyethanol); 1H NMR (DMSO-d6) 8.05 (br s, 2H, NH2), 
8.00 (s, 1H, Ar), 7.96 (s, 1H, NH), 7.77 (d, 1H, Ar, J= 7.8 Hz), 7.69 (d, 1H, Ar, J= 7.7 Hz), 7.47-7.38 
(m, 4H, 3ar + NH), 7.07 (d, 2H, Ar, J= 8.8 Hz), 4.54 (s, 2H, SCH2), 3.90 (d, 2H, OCH2, J= 7.0), 1.23-
1.28 (m, 1H, CH), 0.58-0.61 (m, 2H, CHeq), 0.33-0.37 (m, 2H, CHax); IR 3441, 3387, 3356, 3169, 
2212, 1635. Anal. Calcd for C25H21N5O2S. 
Methyl 3-{[(6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl)thio]methyl} 
benzoate 14. 
Yield 58%; mp 158-160 °C (MeOH); 1H NMR (DMSO-d6) 8.10 (s, 1H, ar), 7.90-8.35 (br s, 2H, NH2), 
7.84-7.87 (m, 2H, Ar), 7.44-7.49 (m, 3H, Ar), 7.07 (d, 2H, ar, J= 8.8 Hz), 4.59 (s, 2H, SCH2), 3.90 
(d, 2H, OCH2 J= 7.04), 3.86 (s, 3H, OCH3), 1.23-1.27 (m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 0.34-





Yield 63%; mp 226-228 °C (EtOH); 1H NMR ( DMSO-d6) 11.8 (s, 1H, NH), 8.07 (br s, 2H, NH2), 
7.47 (d, 2H, Ar, J = 8.2 Hz), 7.09 (d, 2H, Ar, J = 8.2 Hz); 6.90 (br s, 2H, CH, Ar), 4.49 (s, 2H, SCH2), 
3.90 (d, 2H, OCH2, J = 8.0 Hz), 1.23-1.29 (m, 1H, CH), 0.62-0.58 (m, 2H, CHeq), 0.39-0.35 (m, 2H, 
CHax); 13C NMR (DMSO-d6): 166.59, 160.74, 160.32, 158.58, 155.20, 143.02, 130.64, 126.03, 




Yield 32%; column chromatography, eluting system CHCl3/MeOH, 9:1); mp 186-188 °C (EtOH); 
1H 
NMR (DMSO-d6) 11.97 (s, 1H, NH), 8.04 (br s, 2H, NH2), 7.59 (s, 1H, Ar), 7.47 (d, 2H, Ar, J = 8.5 
Hz), 7.18 (s, 1H, Ar), 7.08 (d, 2H, Ar J= 8.5 Hz), 4.40 (s, 2H, SCH2), 3.90 (d, 2H, OCH2, J= 6.9 Hz), 
1.23-1.27 (m, 1H, CH), 0.63- 0.57 (m, 2H, CHeq), 0.34-0.37 (m, 2H, CHax); 13C NMR (DMSO-d6): 
167.24, 160.67, 160.18, 158.49, 130.63, 126.16, 116.02, 114.95, 93.81, 86.05, 72.73, 10.53, 3.60; IR 
3318, 3205, 3080, 2212. Anal. Calcd for C21H18N6OS. 
2-Amino-4-[4-(cyclopropylmethoxy)phenyl]-6-{[(4,5-dihydro-1H-imidazol-2-
yl)methyl]thio}pyridine-3,5-dicarbonitrile 17. 
Yield 37%; preparative TLC, eluent EtOAC/cyclohexane/MeOH, 6:3:1); mp 260-262 °C (2-
propanol/EtOAc); 1H NMR (DMSO-d6) 7.40 (d, 2H, Ar J = 8.5 Hz), 7.19 (s, 2H, NH2), 7.12 (d, 2H, 
Ar J = 8.1 Hz), 6.44 (s, 1H, NH), 5.82 (s, 2H, SCH2), 3.92 (d, 2H, OCH2, J = 7.1 Hz), 3.77 (t, 2H, 
CH2, J = 9.3 Hz), 3.23 (t, 2H, CH2, J = 10.4 Hz), 1.31- 1.24 (m, 1H, CH), 0.68- 0.58 (m, 2H, CHeq), 
0.35 – 0.30 (m, 2H, CHax). Anal. Calcd for C21H20N6OS. 
2-{[(1H-Benzo[d]imidazol-2-yl)methyl]thio}-6-amino-4-[4-(cyclopropylmethoxy)phenyl]pyridine-
3,5-dicarbonitrile 18. 
Yield 64%; mp >300 °C (MeOH); 1H NMR (DMSO-d6) 12.3 (br s, 1H, NH), 7.9-8.4 (br s, 2H, NH2), 
7.57 (d, 1H, Ar, J= 7.8 Hz), 7.46-7.48 (m, 3H, Ar), 7.15-7.20 (m, 2H, Ar), 7.09 (d, 2H, ar, J= 8.7 Hz), 
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4.71 (s, 2H, CH2), 3.9 (d, 2H, OCH2, J= 7.1 Hz), 1.22-1.30 (m, 1H, CH), 0.57-0.62 (m, 2H, CHeq), 
0.33-0.37 (m, 2H, CHax); IR 3396, 3331, 2210. Anal. Calcd for C25H20N6OS. 
2-{[(1H-Pyrazol-5-yl)methyl]thio}-6-amino-4-[4-(cyclopropylmethoxy)phenyl]pyridine-3,5-
dicarbonitrile 19. 
Yield 37%; mp 133-136 °C (EtOH/cyclohexane); 1H NMR (DMSO-d6) 12.7 (br s, 1H, NH), 8.0 (br 
s, 2H, NH2), 7.67 (br s, 1H, Ar), 7.47 (d, 2H, Ar, J= 8.3 Hz), 7.09 (d, 2H, Ar, J= 8.5 Hz), 6.32 (s, 1H, 
Ar), 4.49 (s, 2H, SCH2), 3.91 (d, 2H, OCH2, J= 6.9), 1.22-1.26 (m, 1H, CH), 0.58-0.62 (m, 2H, CHeq), 
0.36-0.40 (m, 2H, CHax). Anal. Calcd for C21H18N6OS. 
2-{[(1H-1,2,4-Triazol-5-yl)methyl]thio}-6-amino-4-[4-(cyclopropylmethoxy)phenyl]pyridine-3,5-
dicarbonitrile 20. 
Yield 72%; mp 240-242 °C (EtOH/Et2O); 
1H NMR (DMSO-d6) 13.9 (br s, 1H, NH ), 8.3 (br s, 1H, 
Ar), 8.10 (br s, 2H, NH2), 7.48 (d, 2H, Ar, J= 7.8 Hz), 7.09 (d, 2H, Ar, J= 8.5 Hz), 4.59 (s, 2H, SCH2), 
3.91 (d, 2H, OCH2, J= 7.1 Hz), 1.23-1.29 (m, 1H, CH), 0.57-0.62 (m, 2H, CHeq), 0.34-0.37 (m, 2H, 
CHax); IR 3441, 3323, 3207, 2212. Anal. Calcd for C20H17N7OS. 
2-{[(1H-Tetrazol-5-yl)methyl]thio}-6-amino-4-[4-(cyclopropylmethoxy)phenyl]pyridine-3,5-
dicarbonitrile 21. 
Yield 64%; mp 225-227 °C (EtOH/Et2O); 
1H NMR (DMSO-d6) 16.10 (br s, 1H, NH), 8.00 (br s, 2H, 
NH2), 7.47 (d, 2H, Ar, J= 8.6 Hz), 7.09 (d, 2H, Ar, J= 8.6 Hz ), 4.78 (s, 2H, SCH2), 3.91 (d, 2H, 
OCH2, J= 7.0 Hz), 1.24-1.28 (m, 1H, CH), 0.58-0.61 (m, 2H, CHeq), 0.34-0.37 (m, 2H, CHax); IR 
3442, 3323, 3224, 2225, 2208. Anal. Calcd for C19H16N8OS. 
2-Amino-6-{[(2-aminothiazol-4-yl)methyl]thio}-4-[4-(cyclopropylmethoxy)phenyl]pyridine-3,5-
dicarbonitrile 22. 
Yield 87%; mp 238-240 °C (EtOH/Et2O); 
1H NMR (DMSO-d6) 8.02 (br s, 2H, NH2), 7.46 (d, 2H, 
Ar, J= 8.7 Hz), 7.08 (d, 2H, Ar, J= 8.7 Hz), 6.98 (br s, 2H, NH2), 6.63 (s, 1H, Ar), 4.31 (s, 2H, SCH2), 
3.90 (d, 2H, OCH2, J= 7.0 Hz), 1.23-1.29 (m, 1H, CH), 0.57-0.62 (m, 2H, CHeq), 0.34-0.37 (m, 2H, 





Yield 40%; mp 235-237 °C (EtOH); 1H NMR (DMSO-d6) 8.99 (s, 1H, Ar), 8.75 – 7.78 (m, 2H, NH2), 
8.04 (s, 1H, Ar), 7.47 (d, 2H, Ar, J= 8.7 Hz), 7.08 (d, 2H, Ar, J= 8.8 Hz), 6.03 (s, 2H, CH2), 3.90 (d, 
2H, CH2, J = 7.1 Hz), 1.32- 1.24 (m, 1H, CH), 0.64- 0.54 (m, 2H, CHeq), 0.38-0.32 (m, 2H CHax); 
IR 3311, 2212. Anal. Calcd for C20H17N7OS. 
2-Amino-4-[4-(cyclopropylmethoxy)phenyl]-6-[(pyridin-3-ylmethyl)thio]pyridine-3,5-dicarbonitrile 
24. 
Yield 80%; mp 190-192 °C (MeOH); 1H NMR (DMSO-d6) 8.7 (s, 1H, Ar), 8.45 (s, 1H, Ar), 8.11 (br 
s, 2H, NH2), 7.94 (d, 1H, Ar, J= 5.7 Hz), 7.42 (d, 2H, Ar, J= 6.8 Hz), 7.35-7.37 (m, 1H, Ar), 7.05 (d, 
2H, ar, J= 6.9 Hz), 4.48 (s, 2H, SCH2), 3.86 (d, 2H, OCH2, J= 7.0 Hz), 1.19-1.25 (m, 1H, CH), 0.56-
0.59 (m, 2H, CH eq), 0.30-0.34 (m, 2H, CH ax); IR 3369, 2212. Anal. Calcd for C23H19N5OS. 
2-{[6-Amino-3,5-dicyano-4-(4-ethoxyphenyl)pyridin-2-yl]thio}-N-methylacetamide 25. 
Yield 32%; mp 262-264 °C (EtOH); 1H NMR (DMSO-d6) 8.1-7.9 (m, 3H, NH + NH2), 7.48 (d, 2H, 
Ar, J= 8.5 Hz), 7.09 (d, 2H, Ar, J= 8.4 Hz), 4.12 (q, 2H, OCH2, J= 7.2 Hz,), 3.88 (s, 2H, SCH2), 2.61 
(d, 3H, CH3, J= 4.6 Hz), 1.36 (t, 3H, CH3, J= 6.8 Hz); 
13C NMR (DMSO-d6): 167.78, 166.54, 160.15, 
158.57, 130.67, 126.05, 115.93, 114.94, 93.63, 86.73, 63.83, 33.71, 26.56, 15.07; IR 3394, 3223, 
2210, 1637. Anal. Calcd for C18H17N5O2S. 
2-{[(1H-Imidazol-2-yl)methyl]thio}-6-amino-4-(4-ethoxyphenyl)pyridine-3,5-dicarbonitrile 26. 
Yield 41%; column chromatography, eluting system EtOAc/cyclohexane/MeOH, 6:3:1); mp 242-244 
°C (EtOH); 1H NMR (DMSO-d6) 11.84 (s, 1H, NH), 8.1 (br s, 2H, NH2), 7.47 (d, 2H, Ar, J= 8.6 Hz), 
7.10-7.08 (m, 3H, Ar), 6.96 (s, 1H, Ar), 4.50 (s, 2H, SCH2), 4.10 (q, 2H, OCH2, J= 6.8 Hz), 1.36 (t, 
3H, CH3, J= 6.8 Hz); 
13C NMR (DMSO-d6): 166.60, 160.65, 160.32, 158.56, 143.01, 130.67, 126.06, 





Yield 29%; column chromatography, eluting system EtOAc/cyclohexane/MeOH, 5:5:1); mp 195-197 
°C (EtOH); 1H NMR (DMSO-d6) 12.72 (s, 1H, NH), 8.05 (BR s, 2H, NH2), 7.65 (s, 1H, Ar), 7.47 (d, 
2H, Ar, J= 8.3 Hz), 7.08 (d, 2H, Ar, J= 8.4 Hz), 6.31 (s, 1H, Ar), 4.48 (s, 2H, SCH2), 4.11 (q, 2H, 
OCH2, J= 6.8 Hz), 1.36 (t, 3H, CH3, J= 6.8 Hz); IR 3456, 3319, 3215, 2218. Anal. Calcd for 
C19H16N6OS. 
2-{[(1H-Pyrazol-5-yl)methyl]thio}-4-(4-(allyloxy)phenyl)-6-aminopyridine-3,5-dicarbonitrile 28. 
Yield 65%; preparative TLC, eluent CH2Cl2/MeOH, 9.5:0.5); mp 129-131°C (EtOH); 
1H NMR 
(DMSO-d6): 12.71 (br s, 1H, NH), 8.08 (br s, 2H, NH2), 7.59 (br s, 1H, Ar), 7.49 (d, 2H, Ar, J= 8.7 
Hz), 7.12 (d, 2H, Ar, J= 8.7 Hz), 6.32 (d, 1H, Ar, J = 2 Hz), 6.13-6.03 (m, 1H, CH), 5.44 (dd, 1H, 
CH, J= 17.3, 1.6 Hz), 5.30 (d, 1H, CH, J= 10.4 Hz), 4.66 (d, 2H, OCH2, J= 5.2 Hz), 4.49 (s, 2H, 
SCH2); 
13C NMR (DMSO-d6): 160.25, 160.23, 158.49, 133.86, 130.67, 128.81, 126.41, 125.65, 
118.35, 115.95, 115.18, 111.08, 109.95, 105.12, 93.71, 86.31, 68.84; IR 3335, 3179, 2210. Anal. 
Calcd for C20H16N6OS. 
 
4-(Cyclobutylmethoxy)benzaldehyde 29 [35]. 
To a solution of 4-hydroxybenzaldehyde (12.3 mmol) in anhydrous acetone (20 mL), potassium 
carbonate (18.5 mmol) was added, followed by the cyclobutylmethyl bromide (18.5 mmol). The 
mixture was heated at reflux for 36 h. Then, the mixture was cooled to rt and the insoluble material 
was filtered and washed with acetone (3 x 20 mL). The resulting filtrates were collected and 
evaporated under vacuum, affording an oily residue which was dissolved in EtOAc (150 mL). The 
organic layer was washed with 25% NaOH solution (4x30 mL), with water (3x30 mL) and then dried 
(Na2SO4). After evaporation of the solvent, the desired compound was obtained as a viscous oil. The 
product was pure enough to be used without further purification. Yield 67%; 1H NMR (DMSO-d6) 
9.86 (s, 1H, CHO), 7.85 (d, 2H, Ar, J= 8.8 Hz), 7.11 (d, 2H, Ar, J= 8.4 Hz), 4.06 (d, 2H, OCH2, J= 




N-[4-(2,2-Dicyanovinyl)phenyl]acetamide 36 [37]. 
Malononitrile (17.3 mmol) and piperidine (two drops) were added to a solution of commercially 
available 4-acetamidobenzaldehyde 34 (17.3 mmol) in EtOH (20 mL). The mixture was heated at 
reflux for 2h, then cooled to rt affording an orange solid which was filtered, washed with Et2O (5 mL) 
and petroleum ether (2 ml), and recrystallized. Yield 63%; mp 234-236 °C (EtOH); 1H NMR (DMSO-
d6) 10.51 (s, 1H, NH), 8.37 (s, 1H, CH), 7.94 (d, 2H, Ar, J= 8.4 Hz), 7.80 (d, 2H, Ar, J= 8.8 Hz), 2.11 
(s, 3H, CH3); IR 2224, 1693. Anal. Calcd for C12H9N3O. 
 
General Procedure for the Synthesis of 2-Amino-4-Aryl-6-(phenylthio)pyridine-3,5-
dicarbonitriles 37-41, 43. 
To a stirred solution of the suitable aldehyde 29 [35], 30-33, 35 (10 mmol), malononitrile (20 mmol) 
and DBU (5% mol) in 10% aqueous EtOH (20 mL), thiophenol (10 mmol) was added after 20 min. 
Thus, the reaction mixture was stirred at 55°C until the disappearance of the starting material (TLC 
monitoring). The suspension was then cooled to rt and a solid precipitated which was collected by 
filtration, washed with Et2O (5-10 mL) and then dried in oven at 60 °C overnight. The crude products 
were purified by crystallization. 
2-Amino-4-[4-(cyclobutylmethoxy)phenyl]-6-(phenylthio)pyridine-3,5-dicarbonitrile 37. 
Yield 18%; mp 180-182 °C (MeOH); 1H NMR (DMSO-d6) 7.7 (br s, 2H, NH2), 7.61-7.60 (m, 2H, 
Ar), 7.51-7.49 (m, 5H, Ar), 7.12 (d, 2H, Ar, J = 8.6 Hz), 4.05 (d, 2H, OCH2, J = 6.5 Hz), 2.77-2.75 
(m, 1H, CH), 2.11-2.09 (m, 2H, CH2), 1.93-1.89 (m, 4H, 2CH2); IR 3348, 3280, 2216. Anal. Calcd 
for C24H20N4OS. 
2-Amino-4-(4-isobutoxyphenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile 38. 
Yield 26%; mp 181-183 °C (MeOH); 1H NMR (DMSO-d6) 7.74 (s, 2H, NH2), 7.61-7.59 (m, 2H, ar), 
7.50-7.49 (m, 5H, Ar), 7.11 (d, 2H, Ar, J= 8.8 Hz), 3.84 (d, 2H, OCH2, J= 6.4 Hz), 2.09-2.02 (m, 1H, 




Yield 37%; mp 252-254 °C (2-propanol); 1H NMR (DMSO-d6) 7.60 (s, 2H, NH2), 7.62-7.60 (m, 2H, 
Ar), 7.58-7.48 (m, 5H, Ar), 7.11 (d, 2H, Ar, J= 8.8 Hz), 4.13 (q, 2H, OCH2, J= 6.8 Hz), 1.37 (t, 3H, 
CH3, J= 7.2 Hz); IR 3344, 3215, 2216. Anal. Calcd for C21H16N4OS. 
4-[4-(Allyloxy)phenyl]-2-amino-6-(phenylthio)pyridine-3,5-dicarbonitrile 40. 
Yield 28%; mp 234-236 °C (EtOAc/cyclohexane); 1H NMR (DMSO-d6): 7.77 (s, 2H, NH2), 7.61-
7.60 (m, 2H, Ar), 7,59-7.58 (m, 3H, Ar), 7.51 (d, 2H, Ar, J= 8.8 Hz), 7.14 (d, 2H, Ar, J= 8.8 Hz), 
6.13-6.03 (m, 1H, CH), 5.45 (dd, 1H, CH, J=17.2, 1.6 Hz), 5.30 (d, 1H, CH, J=10.5Hz), 4.67 (d, 2H, 
OCH2, J= 5.6 Hz); IR 3358, 3215, 2214, 1624. Anal. Calcd for C22H16N4OS. 
2-Amino-4-{4-[(2-methylallyl)oxy]phenyl}-6-(phenylthio)pyridine-3,5-dicarbonitrile 41. 
Yield 25%; mp 198-200 °C (EtOH); 1H NMR (DMSO-d6) 7.76 (s, 2H, NH2), 7.60-7.61 (m, 2H, ar), 
7.60-7.59 (m, 3H, Ar), 7.55 (d, 2H, Ar, J= 8.4 Hz), 7.14 (d, 2H, Ar, J= 8.4 Hz), 5.11 (d, 1H, CH), 
5.00 (d, 1H, CH), 4.58 (s, 2H, CH2), 1.81 (s, 3H, CH3); IR 3481, 3369, 2212. Anal. Calcd for 
C23H18N4OS. 
2-Amino-4-[4-(cyclopropylmethoxy)phenyl]-6-(phenylthio)pyridine-3,5-dicarbonitrile 43. 
Yield 33%; mp 261-263 °C (EtOH); 1H NMR (DMSO-d6) 7.70 (br s, 2H, NH2), 7.60-7.62 (m, 2H, 
Ar), 7.48-7.51 (m, 5H, Ar), 7.10 (d, 2H, Ar, J = 8.1 Hz), 3.92 (d, 2H, CH2, J = 7.8 Hz), 1.25-1.28 (m, 
1H, CH), 0.58-0.62 (m, 2H, 2CHeq), 0.36-0.38 (m, 2H, 2CHax); IR 3330, 3220, 2224. Anal. Calcd 
for C23H18N4OS. 
 
N-{4-[2-Amino-3,5-dicyano-6-(phenylthio)pyridin-4-yl]phenyl}acetamide 42 [37]. 
A solution of compound 36 [37] (5.4 mmol), malononitrile (5.4 mmol), thiophenol (5.4 mmol) and 
Et3N (0.54 mmol) in EtOH (30 mL) was heated at reflux for 2h. Then, after cooling to rt a yellow 
solid was obtained which was filtered and washed with Et2O (5 mL). Yield 44%; mp > 300°C (EtOH); 
1H NMR (DMSO-d6) 10.24 (s, 1H, NH), 7.76 (s, 2H, NH2), 7.74 (m, 2H, Ar), 7.61-7.60 (m, 5H, Ar), 





General Procedure For the Synthesis of 2-Amino-4-Aryl-6-mercaptopyridine-3,5-
dicarbonitriles 44-50. 
To a stirred solution of the suitable 6-phenylsulfanyl derivative 37-43 (10 mmol) in anhydrous DMF 
(1 mL) maintained at rt and under nitrogen atmosphere, an excess of sodium sulfite (33 mmol) was 
added. The reaction mixture was heated at 80 °C for 2 h. Then, 1N HCl (25 mL) was added followed 
by addition of 6N HCl (5 mL) to obtain a huge precipitate which was filtered and washed with water 
(20 mL) and Et2O (5 mL). The crude derivatives were purified by crystallization. 
2-Amino-4-[4-(cyclobutylmethoxy)phenyl]-6-mercaptopyridine-3,5-dicarbonitrile 44. 
Yield 84%; mp 256-259 °C (EtOH); 1H NMR (DMSO-d6) 12.95 (s, 1H, SH), 7.08 (s, 2H, NH2), 7.46 
(d, 2H, Ar, J= 8.0 Hz), 7.09 (d, 2H, Ar, J= 8.4 Hz), 4.04 (d, 2H, OCH2, J= 6 Hz), 2.87-2.73 (m, 1H, 
CH), 2.10-1.92 (m, 2H, CH2), 1.90-1.89 (m, 4H, 2CH2); IR 3474, 3335, 2214. Anal. Calcd for 
C18H16N4OS. 
2-Amino-4-(4-isobutoxyphenyl)-6-mercaptopyridine-3,5-dicarbonitrile 45. 
Yield 86%; mp 210-213 °C (EtOH); 1H NMR (DMSO-d6) 13.02 (s, 1H, SH), 7.77 (s, 2H, NH2), 7.45 
(d, 2H, Ar, J= 8.8 Hz), 7.09 (d, 2H, Ar, J= 8.4 Hz), 3.83 (d, 2H, CH2, J= 6.4 Hz), 2.06-2.03 (m, 1H, 
CH), 1.02 (s, 3H, CH3), 0.99 (s, 3H, CH3). Anal. Calcd for C17H16N4OS. 
2-Amino-4-(4-ethoxyphenyl)-6-mercaptopyridine-3,5-dicarbonitrile 46 [38]. 
Yield 76%; mp: 290-292 °C (EtOH); 1H NMR (DMSO-d6) 12.99 (s, 1H, SH), 8.11 (s, 2H, NH2), 7.54 
(d, 2H, Ar, J= 8.8 Hz), 7.14 (d, 2H, Ar, J= 8.8 Hz), 4.14 (q, 2H, CH2, J= 6.8 Hz), 1.38 (t, 3H, CH3, 
J= 6.8 Hz); IR 3336, 3117, 2212. Anal. Calcd for C15H12N4OS. 
4-[4-(Allyloxy)phenyl]-2-amino-6-mercaptopyridine-3,5-dicarbonitrile 47 [13]. 
Yield 84%; mp 208-211 °C (EtOAc); 1H NMR (DMSO-d6) 12.98 (s, 1H, SH); 7.90 (s, 2H, NH2); 
7.47 (d, 2H, Ar, J= 8.6 Hz); 7.12 (d, 2H, Ar, J= 8.6 Hz); 6.11-6.04 (m, 1H, CH); 5.45 (dd, 1H, CH, 
J= 17.2, 1.2 Hz,), 5.30 (dd, 1H, CH, J= 10.4, 1.2 Hz), 4.66 (d, 2H, OCH2, J= 5.6 Hz,); IR 3476, 3319, 




Yield 72%; mp 180-183 °C dec. (EtOH); 1H NMR (DMSO-d6) 12.98 (s, 1H, SH), 8.11 (br s, 2H, 
NH2), 7.53 (d, 2H, Ar, J= 7.4 Hz), 7.08 (d, 2H, Ar, J= 8.8), 5.09 (s, 1H, CH), 4.90 (s, 1H, CH), 4.58 
(s, 2H, OCH2), 1.80 (s, 3H, CH3). Anal. Calcd for C17H14N4OS. 
N-[4-(2-amino-3,5-dicyano-6-mercaptopyridin-4-yl)phenyl]acetamide 49 [37]. 
Yield 40%; mp 275-277 °C dec. (EtOH/EtOAc); 1H NMR (DMSO-d6) 12.94 (s, 1H, SH), 10.37 (s, 
1H, NH), 8.19 (s, 2H, NH2), 7.73 (d, 2H, Ar, J= 8.0 Hz), 7.44 (d, 2H, Ar, J= 8.0 Hz), 2.08 (s, 3H, 
CH3); IR 3317, 3215, 2214, 1539. Anal. Calcd for C15H11N5OS. 
2-Amino-4-[4-(cyclopropylmethoxy)phenyl]-6-mercaptopyridine-3,5-dicarbonitrile 50.  
Yield 80%; mp 168-170 °C (EtOAc); 1H NMR (DMSO-d6) 12.9 (br s, 1H, SH), 7.8 (br s, 2H, NH2), 
7.45 (d, 2H, Ar, J = 8 Hz), 7.08 (d, 2H, Ar, J = 8 Hz), 3.91 (d, 2H, CH2, J = 7.8 Hz), 1.23-1.27 (m, 
1H, CH), 0.57-0.62 (m, 2H, CHeq), 0.33-0.37 (m, 2H, CHax); IR 3309, 3190, 2219. Anal. Calcd for 
C17H14N4OS. 
 
2-Chloro-N-hydroxyacetamide 51 [39]. 
An aqueous 50 % solution of hydroxylamine (12.0 mmol) was added to ethyl chloroacetate (12.0 
mmol) in a 50 ml round bottomed flask and stirred for 5 min at rt. Then, the mixture was cooled at 4 
°C and stirred for 15 min, and finally, re-warmed to rt and stirred for 3 h. The resulting precipitate 
was collected by filtration and used for the next step without any further purification. Yield 53%; mp 




A solution of compound 1 [13,21] (0.71 mmol) and potassium hydroxide (1.42 mmol) in absolute 
EtOH (10 mL) was refluxed for 3h. Then, iced-water (30 mL) was added and the mixture was 
neutralized with 5N HCl. The green solid was collected by filtration, washed with water (10 ml) and 
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with Et2O (5 mL), and then recrystallized. Yield 85%; mp 260-262 °C (Dioxane); 
1H NMR (DMSO-
d6) 7.39 (d, 2H, Ar, J= 8.0 Hz), 7.27 (br s, 2H, NH2), 7.12 (d, 2H, Ar, J= 8.4 Hz), 6.96 (br s, 2H, 
NH2), 5.70 (s, 2H, NH2), 3.91 (d, 2H, OCH2, J= 6.8 Hz), 1.30-1.23 (m, 1H, CH), 0.62-0.58 (m, 2H, 
CHeq), 0.38-0.34 (m, 2H, CHax); 13C NMR (DMSO-d6): 167.23, 163.83, 160.08, 158.93, 152.76, 
146.75, 130.06, 125.74, 116.43, 115.29, 114.78, 93.35, 90.92, 72.71, 10.57, 3.62; IR 3466, 3452, 
3346, 3315, 3136, 2214, 1629. Anal. Calcd for C19H17N5O2S. 
 
Pharmacology  
Cell culture and membrane preparation. CHO cells transfected with hA1, hA2A, hA2B and hA3 ARs 
were grown adherently and maintained in Dulbecco’s modified Eagle’s medium with nutrient mixture 
F12, containing 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 μg/ml), l-glutamine 
(2 mM), geneticine (G418; 0.2 mg/ml) at 37°C in 5% CO2/95% air until the use in cAMP assays [54]. 
For membrane preparation the culture medium was removed, and the cells were washed with 
phosphate-buffered saline and scraped off T75 flasks in ice-cold hypotonic buffer (5 mM Tris HCl, 
1 mM EDTA, pH 7.4). The cell suspension was homogenized with a Polytron, centrifuged for 30 min 
at 40000 g at 4°C and the resulting membrane pellet was used for competition binding experiments 
[54]. 
Competition binding experiments. All synthesized compounds have been tested for their affinity to 
hA1, hA2A and hA3 ARs. Competition experiments to hA1 ARs were carried out incubating 1 nM [
3H]-
8-cyclopentyl-1,3-dipropylxanthine ([3H]-DPCPX) with membrane suspension (50 μg of protein/100 
μl) and different concentrations of the examined compounds at 25°C for 90 min in 50 mM Tris HCl, 
pH 7.4. Non-specific binding was defined as binding in the presence of 1 μM DPCPX and was always 
< 10% of the total binding [54]. Inhibition experiments to hA2A ARs were performed incubating the 
radioligand [3H]-ZM241385 (1 nM) with the membrane suspension (50 μg of protein/100 μl) and 
different concentrations of the examined compounds for 60 min at 4°C in 50 mM Tris HCl (pH 7.4), 
10 mM MgCl2. Non-specific binding was determined in the presence of ZM241385 (1 μM) and was 
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about 20% of the total binding [55]. Competition binding experiments to A3 ARs were carried out 
incubating the membrane suspension (50 μg of protein/100 μl) with 0.5 nM [125I]-N6-(4-
aminobenzyl)-N-methylcarboxamidoadenosine ([125I]-ABMECA) in the presence of different 
concentration of the examined compounds for an incubation time of 120 min at 4°C in 50 mM Tris 
HCl (pH 7.4), 10 mM MgCl2, 1 mM EDTA. Non-specific binding was defined as binding in the 
presence of 1μM ABMECA and was always < 10% of the total binding [56]. Bound and free 
radioactivity were separated by filtering the assay mixture through Whatman GF/B glass fiber filters 
using a Brandel cell harvester (Brandel Instruments, Unterföhring, Germany). The filter bound 
radioactivity was counted by Packard Tri Carb 2810 TR scintillation counter (Perkin Elmer). 
Cyclic AMP assays. CHO cells transfected with hAR subtypes were washed with phosphate-buffered 
saline, detached with tripsine and centrifuged for 10 min at 200 g. Cells were seeded in 96-well white 
half-area microplate (Perkin Elmer, Boston, USA) in a stimulation buffer composed of Hank 
Balanced Salt Solution, 5 mM HEPES, 0.5 mM Ro 20-1724, 0.1% BSA. The examined compounds 
(1 nM - 1µM) were tested alone and/or in the presence of NECA, 100 nM. cAMP levels were then 
quantified by using the AlphaScreen cAMP Detection Kit (Perkin Elmer, Boston, USA) following 
the manufacturer's instructions [57]. At the end of the experiments, plates were read with the Perkin 
Elmer EnSight Multimode Plate Reader. 
Data Analysis. The protein concentration was determined according to a Bio-Rad method with bovine 
albumin as a standard reference. Inhibitory binding constant (Ki) values were calculated from those 
of IC
50
 according to Cheng & Prusoff equation Ki = IC50/(1+[C*]/KD*), where [C*] is the 
concentration of the radioligand and KD* its dissociation constant [56]. Ki and IC50 values were 
calculated by non-linear regression analysis using the equation for a sigmoid concentration-response 
curve (Graph-PAD Prism, San Diego, CA, U.S.A).  
 
Molecular Modelling  
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Homology modelling and energy minimization studies were carried out using MOE (Molecular 
Operating Environment, version 2014.09) suite [47]. All ligand structures were optimized using 
RHF/AM1 semiempirical calculations and the software package MOPAC [48] implemented in MOE 
was used for these calculations. 
Homology modelling of the hA2B AR. Homology models of the hA2B AR were built using recently 
solved X-ray structures of the hA2A AR in complex with Ado and UK-432097 as templates, both 
structures being retrieved from Protein Data Bank (pdb code: 2YDO; 3.0-Å resolution [45] and pdb 
code: 3QAK; 2.7-Å resolution [46], respectively). A multiple alignment of the hAR primary 
sequences was built within MOE as preliminary step. For all hA2B AR models, the boundaries 
identified from the used X-ray crystal structure of hA2A AR were then applied for the corresponding 
sequences of the TM helices of the hA2B AR. The missing loop domains were built by the loop search 
method implemented in MOE. Once the heavy atoms were modelled, all hydrogen atoms were added, 
and the protein coordinates were then minimized with MOE using the AMBER99 force field [58] 
until the Root Mean Square (RMS) gradient of the potential energy was less than 0.05 kJ mol-1 Å-1. 
Reliability and quality of these models were checked using the Protein Geometry Monitor application 
within MOE, which provides a variety of stereochemical measurements for inspection of the 
structural quality in a given protein, like backbone bond lengths, angles and dihedrals, Ramachandran 
φ-ψ dihedral plots, and quality of side chain rotamer and non-bonded contact. 
Molecular docking analysis. All compound structures were docked into the binding site of the hA2B 
AR structures using three docking tools: the Induced Fit docking protocol of MOE, the genetic 
algorithm docking tool of CCDC Gold [49], and the Lamarckian genetic algorithm of Autodock 
[50,51]. The Induced Fit docking protocol of MOE is divided into several stages: Conformational 
Analysis of ligands. The algorithm generated conformations from a single 3D conformation by 
conducting a systematic search. In this way, all combinations of angles were created for each ligand. 
Placement. A collection of poses was generated from the pool of ligand conformations using Alpha 
Triangle placement method. Poses were generated by superposition of ligand atom triplets and triplet 
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points in the receptor binding site. The receptor site points are alpha sphere centres which represent 
locations of tight packing. At each iteration, a random conformation was selected, a random triplet of 
ligand atoms and a random triplet of alpha sphere centres were used to determine the pose. Scoring. 
Poses generated by the placement methodology were scored using the Alpha HB scoring function, 
which combines a term measuring the geometric fit of the ligand to the binding site and a term 
measuring hydrogen bonding effects. Induced Fit. The generated docking conformations were 
subjected to energy minimization within the binding site and the protein sidechains are included in 
the refinement stage. In detail, the protein backbone is set as rigid while the side chains are not set to 
“free to move” but are set to “tethered”, where an atom tether is a distance restraint that restrains the 
distance not between two atoms but between an atom and a fixed point in space. Rescoring. 
Complexes generated by the Induced Fit methodology stage were scored using the Alpha HB scoring 
function. Gold tool was used with default efficiency settings through MOE interface, by selecting 
GoldScore as scoring function [49]. Autodock 4.2.6 software was used with PyRx interface. 
Lamarckian genetic algorithm was employed for this analysis with the following settings: 50 runs for 
each ligand; 2,500,000 as maximum number of energy evaluations; 27,000 as maximum number of 
generations; 0.02 as rate of gene mutation and 0.8 as rate of crossover. The grid box was set with 50, 
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Table S1. Combustion Analysis data of the newly synthesized compounds                                  
 
compd Formula C H N 
  calcd-found calcd-found calcd-found 
3 C20H19N5O2S 61.05-61.16 4.87-4.78 17.81-17.63 
4 C19H19N5O2S 59.82-59.99 5.02-4.90 18.37-18.21 
43 
 
5 C17H15N5O2S 57.77-57.49 4.28-4.10 19.83-19.98 
6 C18H15N5O2S 59.16-59.32 4.14-4.00 19.18-18.97 
7 C19H17N5O2S 60.14-60.36 4.52-4.39 18.47-18.23 
8 C17H14N6O2S 55.72-55.58 3.85-3.97 22.95-23.09 
9 C20H19N5O2S 61.05-61.37 4.87-4.68 17.81-17.65 
10 C20H19N5O3S 58.66-58.41 4.68-4.52 17.11-17.40 
11 C19H17N5O3S 57.71-57.92 4.34-4.50 17.72-17.49 
12 C20H18N4O3S 60.90-61.28 4.60-4.71 14.21-13.93 
13 C25H21N5O2S 65.91-65.65 4.65-4.43 15.38-15.64 
14 C26H22N4O3S 66.36-66.21 4.72-4.60 11.91-12.19 
15 C21H18N6OS 62.67-62.93 4.51-4.77 20.89-20.61 
16 C21H18N6OS 62.67-62.90 5.51-4.66 20.89-20.57 
17 C21H20N6OS 62.35-62.55 4.99-5.15 20.79-20.51 
18 C25H20N6OS 66.35-66.11 4.46-4.59 18.58-18.81 
19 C21H18N6OS 62.67-62.92 4.51-4.37 20.89-20.53 
20 C20H17N7OS 59.54-59.78 4.25-4.02 24.32-24.08 
21 C19H16N8OS 56.42-56.12 3.99-4.22 27.72-28.00 
22 C21H18N6OS2 58.05-58.33 4.18-3.99 19.35-19.11 
23 C20H17N7OS 59.54-59.77 4.25-4.38 24.32-24.03 
24 C23H19N5OS 66.81-66.55 4.64-4.51 16.95-17.18 
25 C18H17N5O2S 58.84-58.99 4.67-4.43 19.07-18.81 
26 C19H16N6OS 60.62-60.41 4.29-4.50 22.34-22.04 
27 C19H16N6OS 60.62-60.92 4.29-4.44 22.34-22.07 
28 C20H16N6OS 61.84-61.62 4.15-3.98 21.65-21.47 
44 
 
36 C12H9N3O 68.22-67.98 4.30-4.15 19.90-20.21 
37 C24H20N4OS 69.88-69.55 4.89-4.71 13.59-13.83 
38 C23H20N4OS 68.98-69.32 5.04-5.21 14.00-14.29 
39 C21H16N4OS 67.72-67.48 4.33-4.11 15.05-15.37 
40 C22H16N4OS 68.73-68.98 4.20-4.37 14.58-14.30 
41 C23H18N4OS 69.33-69.58 4.56-4.24 14.07-14.32 
42 C21H15N5OS 65.44-65.13 3.92-3.70 18.17-18.39 
43 C23H18N4OS 69.33-69.58 4.56-4.38 14.07-13.80 
44 C18H16N4OS 64.27-64.01 4.80-4.97 16.67-16.88 
45 C17H16N4OS 62.94-63.15 4.98-5.12 17.28-16.99 
46 C15H12N4OS 60.80-61.11 4.08-3.88 18.92-18.68 
47 C16H12N4OS 62.32-62.03 3.93-4.11 18.18-18.42 
48 C17H14N4OS 63.34-63.59 4.38-4.19 17.39-17.12 
49 C15H11N5OS 58.24-57.97 3.59-3.41 22.65-22.91 
50 C17H14N4OS 63.34-63.10 4.38-4.45 17.39-17.63 
52 C19H17N5O2S 60.14-60.43 4.52-4.34 18.47-18.22 
 
 





Figure S1. Compound 15 docked at the binding site of the two hA2B AR receptor models; panel A shows the 
2YDO-based receptor, while panel B shows the 3QAK-based one. The binding mode is highly conserved at 
the two cavities, as well as the interaction with the receptor residues (i.e. Asn254). The different arrangement 
of the residues at the entrance of the cavity (i.e. Glu174) may lead to a diverse orientation of the 2-
substituent without largely modifying the compound conformation. 
 
 
Figure S2. Alternative docking conformation of compound 15 at the hA2B AR receptor model (the 2YDO-based 




An alternative binding mode orients the compounds in a different way with respect to the docking 
conformations described within the main text, and similarly to the one previously described in the literature 
at this receptor [41,42,53]. This binding mode was associated with a good docking score only for some 
derivatives bearing a small R2 substituent, in particular an amide group (1, 5, 8, 9, 10, 25). In detail, the N1 
atom and the 2-amino group of the pyridine core give polar interaction, respectively, with the NH and/or 
carbonyl groups of the Asn2546.55 residue. The interaction between the 2-amino and the Glu174 side chain is 
clearly observable only in the 2YDO-based model. The 5-cyano group of pyridines gets close to His2807.43 and 
Ser2797.42. As for the general binding mode described within the main text, the interaction with these 
residues could be mediated by a bridge water molecule or a reorientation (or different protonation state) of 
His2807.43. The 4-phenyl ring points toward residues of TM1, TM2 and TM7 and again eventual additional 
substituents modulate the interaction with the receptor. The 3-cyano group locates toward the extracellular 
environment in proximity of residues Glu174 and Lys269. The 6-sulfanyl substituent gets in proximity of TM3, 
TM5, and TM6 residues (Leu863.33, Thr893.36, Asn1865.42, Trp2476.48, and His2516.52). In this arrangement, the 
amide group in R2 appears to mimic the analogue function of adenosine-like derivatives as observed at 
several hA2A AR crystal structures, i.e. by interacting with Thr893.36 and His2516.52 (Thr883.36 and His2506.52 in 
the hA2A AR, respectively) [42,52]. 
1H NMR and 13C APT NMR spectra of representative derivatives. 
 
 
The 13C APT (Attached Proton Test) experiment distinguishes between C-H multiplicities. CH and CH3 vectors 
have opposite phases compared to C and CH2. Therefore, the phase of CH and CH3 peaks is 180° different 

















































13C APT NMR spectrum (100 MHz, DMSO-d6) of compound 9. 
 














13C APT NMR spectrum (100 MHz, DMSO-d6) of compound 16. 
 































1H NMR spectrum (400 MHz, DMSO-d6) of compound 25. 
 
 









13C APT NMR spectrum (100 MHz, DMSO-d6) of compound 26. 
 





























1H NMR spectrum (400 MHz, DMSO-d6) of compound 28. 
 








13C APT NMR spectrum (100 MHz, DMSO-d6) of compound 52. 
 
 
 
